CardieX Announces CONNEQT Pulse, the World's First Customizable Dual Blood Pressure and Arterial Health Monitor
Retrieved on:
Tuesday, June 28, 2022
Patient, Kuwait Central Blood Bank, Heart, Pre-eclampsia, Research, Adoption, Index, COVID-19, Company, Coronary circulation, Food, Heart rate, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, GSK, Philip Morris, Atmosphere, HSX, Gold, Andon, AP, Blood pressure, Novartis, Brain, ASX, Alzheimer's disease, Yale University, Ecosystem, Technology, Arm, Health, Hypertension, AstraZeneca, ASF, CDX, DCT, Stroke, OTA, RPM, Risk, Clinical trial, CPT, Cardiovascular disease, Australian Securities Exchange, Physician, Medical device, Medical imaging, Pharmaceutical industry, Pulse, Bayer, ECAPS, GlaxoSmithKline
IRVINE, Calif., June 28, 2022 /PRNewswire/ -- CardieX Limited (ASX: CDX), a global health technology company focused on cardiovascular disease, has together with its manufacturing partner Andon filed a 510(k) premarket submission with the U.S. Food and Drug Administration (FDA) for the CONNEQT Pulse (Pulse) – a world first dual blood pressure and arterial health monitor targeted at the home health, remote patient monitoring, and decentralized clinical trial markets.
Key Points:
- Pulse will also be the first blood pressure monitor to incorporate "over the air" (OTA) customizable display screens based on specific health parameters and disease conditions.
- SphygmoCor technology has been in use for over 20 years by researchers, specialist clinicians, and pharmaceutical companies looking to obtain advanced arterial health insights beyond traditional blood pressure.
- Measuring central blood pressure at the heart is considered to be superior to standard measurements of blood pressure at the arm mainly due to the proximity of the heart to the major organs.
- Arterial Stiffness Factor (ASF): Based on Augmentation Pressure (AP) a clinical standard for measuring arterial stiffness, and other proprietary algorithms.